


## ST3932

<b>Cat. No.:</b>	HY-112840
<b>CAS No.:</b>	1246018-21-2
<b>Molecular Formula:</b>	C <sub>12</sub> H <sub>16</sub> N <sub>8</sub> O
<b>Molecular Weight:</b>	288.31
<b>Target:</b>	Adenosine Receptor
<b>Pathway:</b>	GPCR/G Protein
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	ST3932 is a metabolite of ST1535, acts as an antagonist of adenosine A <sub>2A</sub> receptor, with K <sub>i</sub> s of 8 nM and 33 nM for A <sub>2A</sub> and A <sub>1</sub> receptors, respectively.
<b>IC<sub>50</sub> &amp; Target</b>	K <sub>i</sub> : 8 nM (A <sub>2A</sub> receptor), 33 nM (A <sub>1</sub> receptor) <sup>[1]</sup>
<b>In Vitro</b>	ST3932 is a metabolite of ST1535, acts as an antagonist of adenosine A <sub>2A</sub> receptor, with K <sub>i</sub> s of 8 nM and 33 nM for A <sub>2A</sub> and A <sub>1</sub> receptors, respectively. ST3932 inhibits agonist-induced cAMP accumulation with an IC <sub>50</sub> value of 450 nM <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	ST3932 (10, 20, 40 mg/kg, p.o.) antagonizes haloperidol-induced catalepsy, and increases motor activity in mice. ST3932 (20, 40 mg/kg, i.p.) significantly increases the number of contralateral turns induced by l-DOPA in rats <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### PROTOCOL

<b>Animal Administration</b> <sup>[1]</sup>	<p><b>Mice</b><sup>[1]</sup></p> <p>Catalepsy is induced by haloperidol (2 mg/kg) injected intraperitoneally (i.p.) 2.5 h before oral administration of 10, 20, and 40 mg/kg ST1535, ST3932, ST4206 or vehicle. An additional group without haloperidol (control group) with only vehicle is administered. At time 0 min, successful induction of catalepsy in all animals is checked before compounds administration, then, catalepsy is scored every 60 min for 3 h. Each mouse is gently placed by its forepaws on a wire at a height of 4.5 cm. The catalepsy is measured as the time necessary for the animal to step down with at least one forepaw with a cut off time for each animal of 60 s; after this time the mouse is gently removed from the wire. Catalepsy is recorded using a video-camera and by an observer who is unaware of the treatment<sup>[1]</sup>.</p> <p><b>Rats</b><sup>[1]</sup></p> <p>Two weeks after the unilateral 6-OHDA-lesion, rats are screened on the basis of their contralateral rotation in response to l-DOPA (50 mg/kg i.p.)+benserazide (30 mg/kg i.p.). Rats not showing at least 200 contralateral rotations during 3 h testing period are eliminated from the study. One week later, rats are administered with the threshold dose of l-DOPA (3 mg/kg i.p.)+benserazide (6 mg/kg i.p.) in combination with vehicle (10% sucrose and 0.3% Tween 80 in sterile water i.p.) or with ST1535, ST3932 and ST4206 respectively (10, 20 and 40 mg/kg i.p.). l-DOPA is administered 5 min after vehicle or molecules in study, whereas benserazide is administered 30 min before l-DOPA injection. Contralateral rotations are measured every 10 min for 2 h by Rotameter system<sup>[1]</sup>.</p>
---	---

---

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. ST3932, et al. Animal models of Parkinson's disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535). Eur J Pharmacol. 2015 Aug 15;761:353-61.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA